Genentech: FDA Approves Tecentriq in Combination for Some Lung Cancer Patients
December 06 2018 - 6:18PM
Dow Jones News
By Stephen Nakrosis
Genentech, a member of the Roche Group, on Thursday said the
U.S. Food and Drug Administration approved Tecentriq and
chemotherapy for some patients with a certain type of lung
cancer.
Genentech said the FDA gave its approval to Tecentriq in
combination with Avastin, paclitaxel and carboplatin for the
first-line treatment of patients with metastatic non-squamous
non-small cell lung cancer, with no EGFR or ALK genomic tumor
aberrations.
Approval is based on results of the Phase III IMpower150 study,
which showed that Tecentriq in combination with Avastin and
chemotherapy helped people live significantly longer compared to
Avastin and chemotherapy.
"This Tecentriq regimen has demonstrated a significant survival
benefit in the initial treatment of metastatic non-squamous
non-small cell lung cancer," said Sandra Horning, M.D., chief
medical officer and head of Global Product Development.
The company is working with the FDA on postmarketing commitments
to better understand and characterize the potential effects of
Tecentriq-related anti-drug antibodies and neutralizing
antibodies.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 06, 2018 18:03 ET (23:03 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024